

Barbara J Mintzes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545277/publications.pdf>

Version: 2024-02-01

122
papers

3,618
citations

201674

27
h-index

155660

55
g-index

126
all docs

126
docs citations

126
times ranked

3999
citing authors

#	ARTICLE	IF	CITATIONS
1	Industry sponsorship and research outcome. The Cochrane Library, 2017, 2017, MR000033.	2.8	772
2	A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). Journal of General Internal Medicine, 2021, 36, 3179-3187.	2.6	575
3	The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. Systematic Reviews, 2018, 7, 242.	5.3	146
4	Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy and Childbirth, 2014, 14, 242.	2.4	110
5	Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No. Journal of Public Policy and Marketing, 2002, 21, 194-201.	3.4	106
6	Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Medicine, 2018, 44, 1603-1612.	8.2	97
7	Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ, The, 2015, 350, h2088-h2088.	6.0	89
8	Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001â€“2006). Clinical Therapeutics, 2012, 34, 239-249.e2.	2.5	81
9	Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States. Journal of General Internal Medicine, 2013, 28, 1368-1375.	2.6	79
10	Pathways to independence: towards producing and using trustworthy evidence. BMJ, The, 2019, 367, l6576.	6.0	79
11	Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries. International Journal of Health Policy and Management, 2018, 7, 504-509.	0.9	68
12	Advertising of Prescription-Only Medicines to the Public: Does Evidence of Benefit Counterbalance Harm?. Annual Review of Public Health, 2012, 33, 259-277.	17.4	66
13	Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age and Ageing, 2016, 45, 535-542.	1.6	60
14	Disease Mongering in Drug Promotion: Do Governments Have a Regulatory Role?. PLoS Medicine, 2006, 3, e198.	8.4	60
15	How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Cmaj, 2003, 169, 405-12.	2.0	60
16	Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002â€“2011: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0128312.	2.5	58
17	Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. Cmaj, 2003, 168, 1133-7.	2.0	52
18	Direct to consumer advertising. BMJ: British Medical Journal, 2005, 330, 5-6.	2.3	51

#	ARTICLE	IF	CITATIONS
19	Mental Health Messages in Prominent Mental Health Apps. <i>Annals of Family Medicine</i> , 2018, 16, 338-342.	1.9	46
20	A health app developer's guide to law and policy: a multi-sector policy analysis. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 141.	3.0	45
21	Industry funding of patient and health consumer organisations: systematic review with meta-analysis. <i>BMJ</i> , 2020, 368, l6925.	6.0	44
22	Over half of clinical practice guidelines use non-systematic methods to inform recommendations: A methods study. <i>PLoS ONE</i> , 2021, 16, e0250356.	2.5	40
23	Medicines Information and the Regulation of the Promotion of Pharmaceuticals. <i>Science and Engineering Ethics</i> , 2019, 25, 1167-1192.	2.9	39
24	Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. <i>PLoS ONE</i> , 2013, 8, e68633.	2.5	38
25	Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. <i>Obstetrics and Gynecology</i> , 2016, 127, 553-561.	2.4	37
26	The Sources and Popularity of Online Drug Information: An Analysis of Top Search Engine Results and Web Page Views. <i>Annals of Pharmacotherapy</i> , 2011, 45, 350-356.	1.9	35
27	Conflict of Interest Policies at French Medical Schools: Starting from the Bottom. <i>PLoS ONE</i> , 2017, 12, e0168258.	2.5	28
28	Twelve Years' Experience with Direct-to-Consumer Advertising of Prescription Drugs in Canada: A Cautionary Tale. <i>PLoS ONE</i> , 2009, 4, e5699.	2.5	27
29	Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 231-238.	3.5	27
30	Postpartum domperidone use in British Columbia: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E13-E19.	2.4	25
31	The association between domperidone and ventricular arrhythmia in the postpartum period. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1210-1214.	1.9	25
32	Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. <i>Accountability in Research</i> , 2016, 23, 257-279.	2.4	25
33	A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. <i>BMJ Open</i> , 2017, 7, e016701.	1.9	25
34	Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. <i>JAMA Internal Medicine</i> , 2019, 179, 982.	5.1	21
35	Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis. <i>International Journal of Health Services</i> , 2019, 49, 273-293.	2.5	21
36	Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study. <i>BMJ Open</i> , 2018, 8, e019027.	1.9	19

#	ARTICLE	IF	CITATIONS
37	“Asset exchange” interactions between patient groups and pharmaceutical industry: Australian qualitative study. <i>BMJ</i> , The, 2019, 367, l6694.	6.0	18
38	Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 13.	2.4	17
39	Disease mongering and low testosterone in men: the tale of two regulatory failures. <i>Medical Journal of Australia</i> , 2012, 196, 619-621.	1.7	16
40	The ethics of randomized placebo controlled trials of antidepressants with pregnant women. <i>International Journal of Risk and Safety in Medicine</i> , 2010, 22, 7-16.	0.6	14
41	A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. <i>International Journal of Risk and Safety in Medicine</i> , 2014, 26, 213-225.	0.6	14
42	The Inclusion of Nurses in Pharmaceutical Industry “Sponsored Events. <i>JAMA Internal Medicine</i> , 2016, 176, 1718.	5.1	13
43	Validation of five search filters for retrieval of clinical practice guidelines produced low precision. <i>Journal of Clinical Epidemiology</i> , 2020, 117, 109-116.	5.0	13
44	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.6	12
45	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1424-1442.	4.7	12
46	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.6	12
47	How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study. <i>Australian Health Review</i> , 2019, 43, 474.	1.1	11
48	Direct-to-consumer prescription drug advertising in Canada: permission by default?. <i>Cmaj</i> , 2003, 169, 425-7.	2.0	11
49	Medicine by media: Did a critical television documentary affect the prescribing of cyproterone-estradiol (Diane-35)?. <i>Cmaj</i> , 2005, 173, 1313-1315.	2.0	9
50	Regulating prescription drugs for patient safety: Does Bill C-17 go far enough?. <i>Cmaj</i> , 2014, 186, E287-E292.	2.0	9
51	The marketing of testosterone treatments for age-related low testosterone or “Low T”. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 224-230.	2.3	9
52	A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States 2007 to 2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1054-1063.	1.9	9
53	US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS). <i>Pharmaceutical Medicine</i> , 2020, 34, 135-140.	1.9	9
54	Impact and use of reviews and “overviews of reviews” to inform clinical practice guideline recommendations: protocol for a methods study. <i>BMJ Open</i> , 2020, 10, e031442.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Direct to consumer advertising of prescription drugs. <i>BMJ: British Medical Journal</i> , 2008, 337, a985-a985.	2.3	9
56	Inadequate conflict of interest policies at most French teaching hospitals: A survey and website analysis. <i>PLoS ONE</i> , 2019, 14, e0224193.	2.5	8
57	Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures. <i>Internal Medicine Journal</i> , 2021, 51, 1816-1824.	0.8	8
58	Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 713-722.	2.4	8
59	Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?. <i>Pharmacoeconomics</i> , 2008, 26, 557-566.	3.3	7
60	Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature. <i>Drugs and Aging</i> , 2014, 31, 55-65.	2.7	7
61	Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. <i>British Medical Bulletin</i> , 2015, 116, ldv042.	6.9	7
62	The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters". <i>International Journal of Health Policy and Management</i> , 2016, 5, 329-331.	0.9	7
63	Flawed evidence underpins approval of new cancer drugs. <i>BMJ: British Medical Journal</i> , 2019, 366, l5399.	2.3	7
64	Missing data reporting in clinical pharmacy research. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 2048-2052.	1.0	7
65	Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators. <i>BMJ, The</i> , 2020, 369, m1107.	6.0	7
66	Industry Sponsor Influence in Clinical Trial Reporting in Canada: A Qualitative Interview Study. <i>Clinical Therapeutics</i> , 2022, 44, 374-388.	2.5	7
67	Opinion: Direct-to-consumer advertising of prescription medicines: a counter argument. <i>Future Medicinal Chemistry</i> , 2009, 1, 1555-1560.	2.3	6
68	Secret safety warnings on medicines: A case study of information access requests. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 551-555.	1.9	6
69	Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1416-1429.	2.4	6
70	UK deal over inclisiran. <i>BMJ, The</i> , 2020, 368, m579.	6.0	6
71	“Lines in the sand”: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. <i>BMJ Open</i> , 2021, 11, e045140.	1.9	6
72	Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 185-188.	0.3	6

#	ARTICLE	IF	CITATIONS
73	Should Canada allow direct-to-consumer advertising of prescription drugs?: no. Canadian Family Physician, 2009, 55, 131, 133, 135 passim.	0.4	6
74	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality and Safety, 2022, 31, 179-190.	3.7	6
75	Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States. Journal of Law, Medicine and Ethics, 2016, 44, 602-615.	0.9	5
76	Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. Health Policy, 2018, 122, 250-255.	3.0	5
77	"There are ways" drug companies will get into DTC decisions: How Australian drug and therapeutics committees address pharmaceutical industry influence. British Journal of Clinical Pharmacology, 2021, 87, 2341-2353.	2.4	5
78	Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. British Journal of Cancer, 2022, 126, 144-161.	6.4	5
79	Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. British Journal of Clinical Pharmacology, 2017, 83, 2549-2556.	2.4	5
80	Should Paroxetine Be Used to Treat Depression During Pregnancy?. American Journal of Psychiatry, 2008, 165, 1487-1487.	7.2	4
81	Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. International Journal of Drug Policy, 2022, 105, 103749.	3.3	4
82	Paroxetine is associated with malformation during pregnancy. BMJ: British Medical Journal, 2011, 343, d5060-d5060.	2.3	3
83	Diagnosis, Pathophysiology, and Management of Mood Disorders in Pregnant and Postpartum Women. Obstetrics and Gynecology, 2011, 118, 708.	2.4	3
84	The rise of ambiguous competing interest declarations. BMJ: British Medical Journal, 2018, 361, k1464.	2.3	3
85	A Cohort Study of Psychotropic Prescription Drug Use in Pregnancy in British Columbia, Canada from 1997 to 2010. Journal of Women's Health, 2020, 29, 1339-1349.	3.3	3
86	Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis. Journal of General Internal Medicine, 2022, 37, 290-297.	2.6	3
87	"Drugs to avoid" to improve quality use of medicines: how is Australia faring?. Journal of Pharmaceutical Policy and Practice, 2021, 14, 60.	2.4	3
88	Long-acting antipsychotics: is what we know really so?. Lancet Psychiatry, the, 2021, 8, 651.	7.4	3
89	Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. JCO Oncology Practice, 2022, 18, e1154-e1163.	2.9	3
90	Australian Clinical Trial Authors' Declarations of Industry Ties. Journal of General Internal Medicine, 2022, 37, 3196-3198.	2.6	3

#	ARTICLE	IF	CITATIONS
91	Regulation of formula advertising in the Philippines and promotion and protection of breastfeeding: A commentary on Sobel, Iellamo, Raya, Padilla, OlivÃ© and Nyunt-U. Social Science and Medicine, 2011, 73, 1449-1451.	3.8	2
92	Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 2013, 28, 1395-1395.	2.6	2
93	A Leap of Faith in Antidepressant Treatment?. JAMA Psychiatry, 2013, 70, 1373.	11.0	2
94	When drugs don't make it to market. BMJ, The, 2015, 350, h2852-h2852.	6.0	2
95	Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards. BMC Public Health, 2018, 18, 1322.	2.9	2
96	Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. Pharmacology Research and Perspectives, 2020, 8, e00680.	2.4	2
97	Editorial: Policing the promotion of prescription medicines - the new Medicines Australia Code of Conduct. Australian Prescriber, 2021, 44, 4-6.	1.0	2
98	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	3.2	2
99	Is patient information on prescribed drugs just another form of advertising?. BMJ: British Medical Journal, 2011, 343, d4899-d4899.	2.3	1
100	New UK guidance on industry-health professional collaboration. BMJ, The, 2012, 344, e3952-e3952.	6.0	1
101	Review overemphasises benefits and downplays serious harms. BMJ, The, 2012, 345, e5989-e5989.	6.0	1
102	Response to "Cause of domperidone and risk of ventricular arrhythmia in the postpartum period: Getting to the heart of the matter". Pharmacoepidemiology and Drug Safety, 2017, 26, 865-866.	1.9	1
103	Unbranded advertising of prescription medicines to the public by pharmaceutical companies. The Cochrane Library, 0, , .	2.8	1
104	Are Safety Warnings for Commonly-Used Sleeping Pills Reaching Those who Need them Most?. Journal of Law, Medicine and Ethics, 2019, 47, 442-444.	0.9	1
105	The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system. The Cochrane Library, 2019, , .	2.8	1
106	National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstetrics and Gynecology, 2019, 134, 1115-1117.	2.4	1
107	The "Nuts and Bolts" of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse. Journal of General Internal Medicine, 2020, 35, 3730-3732.	2.6	1
108	Medical, pharmacy and nursing students in the Baltic countries: interactions with the pharmaceutical and medical device industries. BMC Medical Education, 2020, 20, 105.	2.4	1

#	ARTICLE	IF	CITATIONS
109	Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 1039-1045.	1.9	1
110	Antidepressants and pregnancy. <i>Cmaj</i> , 2011, 183, 585-585.	2.0	0
111	Medication safety: opening up the black box. <i>BMJ Quality and Safety</i> , 2013, 22, 702-704.	3.7	0
112	Authors'™ reply to Lee and colleagues. <i>BMJ</i> , The, 2015, 351, h3737.	6.0	0
113	New oral anticoagulants. <i>Cmaj</i> , 2015, 187, 603.1-603.	2.0	0
114	In Reply. <i>Obstetrics and Gynecology</i> , 2016, 128, 406-406.	2.4	0
115	Mental health care and suicide in pregnancy and postpartum. <i>Cmaj</i> , 2017, 189, E1498-E1498.	2.0	0
116	Information and promotional strategies by pharmaceutical companies for clinicians. <i>The Cochrane Library</i> , 0, , .	2.8	0
117	Information and promotional strategies by pharmaceutical companies for clinicians. <i>The Cochrane Library</i> , 2020, , .	2.8	0
118	Reply to Kelly Farrah and David Kaunelis regarding our study "Validation of five search filters for retrieval of clinical practice guidelines produced low precision". <i>Journal of Clinical Epidemiology</i> , 2021, 133, 156-157.	5.0	0
119	A sorry tale of unnecessary secrecy about medicine safety. <i>Internal Medicine Journal</i> , 2021, 51, 1765-1766.	0.8	0
120	Does Venlafaxine Maintenance Therapy Prevent Depression Recurrences or Drug Discontinuation Reactions?. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 865-866.	2.2	0
121	"Drugs to avoid"™: can we improve prescribing appropriateness?. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 162-162.	0.3	0
122	Industry effects on evidence: a case study of long-acting injectable antipsychotics. <i>Accountability in Research</i> , 2024, 31, 2-13.	2.4	0